Pharmaceutical compositions comprising meloxicam
By forming an inclusion complex of meloxicam with SBEβCD and bicarbonate, and combining it with rizatriptan, the formulation addresses meloxicam's solubility issues, achieving rapid and sustained pain relief in conditions like migraine and arthritis.
US12472256B2Active Publication Date: 2025-11-18AXSOME THERAPEUTICS INC
293 Cites 3 Cited by
Patent Information
- Application Number
- US19/228293
- Authority / Receiving Office
- US · United States
- Patent Type
- Patents(United States)
- Current Assignee / Owner
- Priority Date
- 2017-07-25
- Filing Date
- 2025-06-04
- Publication Date
- 2025-11-18
- Estimated Expiration
- 2038-05-18
AI Technical Summary
Technical Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and slow onset of pain relief.
Method used
Formulating meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and bicarbonate to create an inclusion complex, enhancing solubility and bioavailability, and combining it with rizatriptan for rapid and sustained pain relief.
Benefits of technology
The combination significantly increases meloxicam's solubility and absorption rate, providing rapid and sustained pain relief, reducing the need for rescue medication and improving treatment outcomes in conditions like migraine and arthritis.
✦ Generated by Eureka AI based on patent content.
Abstract
Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Need to check novelty before this filing date? Find Prior Art